Why Is BEAM THERAPEUTICS IN (BEAM) Stock Up Today?

Beam Therapeutics shares rose 11.29% to $27.71 on Tuesday, driven by the release of initial Phase 1/2 clinical data for BEAM-301. The one-time liver-targeted gene therapy demonstrated proof of concept for correcting glycogen storage disease type Ia, with two patients in the 40 mg cohort achieving 15 hours of controlled fasting without requiring starch supplementation.

What Happened

The company presented initial results from its ongoing trial at the 33rd European Society for Gene and Cell Therapy conference. The data showed improvements in glucose control and a safety profile consistent with other lipid nanoparticle-based therapies. H.C. Wainwright reiterated its Buy rating and maintained an $80 price target, stating the data strengthens confidence in the asset. Wedbush maintained its Outperform rating but lowered its price target to $28.00.

What The Data Shows

The stock opened at $24.94 and hit a session high of $27.71 at 12:00 PM ET, closing near the high at $27.64. Volume stood at 1.7 million shares, which is 0.8 times the three-month daily average. The stock printed 39 fresh 52-week highs on October 28, 2026, despite trading within a 52-week range of $20.23 to $38.26. Fundamentals show a market cap of $2.4 billion with revenue up 158.9% year-over-year, though the company remains unprofitable with a trailing twelve-month EPS of -$0.84 and a net margin of -55.4%. The stock has a beta of 2.20 and moved 4.9% over the last eight sessions. Recent insider activity includes two sales totaling $1.2 million in the last 90 days, with CEO John M. Evans selling 50,000 shares on October 15, 2026.

What To Watch

Investors will monitor further updates on the BEAM-301 trial and potential expansion of the patient cohort. The stock’s high beta and recent 52-week high activity suggest continued volatility as the market digests the clinical milestones.